Goals, Mission & Vision
Our Goals
The Rare Bronchiectasis Disease Consortium (RBDC) is committed to accelerating therapeutic development for four rare bronchiectasis‑producing diseases, PCD, HID, α1AT deficiency, and STAT3‑HIES, by generating the foundational clinical and biological data the field currently lacks. Our goals are to define the natural history and progression of these conditions, validate and discover biomarkers rooted in our updated Vicious Vortex 2.0 paradigm, and identify treatable traits that can inform future clinical trials. Through integrated longitudinal cohort studies, advanced imaging, multi‑omic biomarker analyses, and mechanistic laboratory investigations, we aim to build the evidence base required to design efficient phase I–II trials and ultimately improve outcomes for individuals living with rare bronchiectasis diseases.
Our Vision
We envision a future in which rare bronchiectasis diseases are understood with the same depth and precision that now guide cystic fibrosis care, where early detection, targeted therapies, and biomarker‑driven clinical decision‑making are standard. By uniting leading investigators, patient advocacy groups, and multidisciplinary scientific teams across four international sites, the RBDC seeks to transform the landscape of rare bronchiectasis research. Our vision is to create a sustainable, data‑rich platform that reveals both shared and disease‑specific pathways of airway injury, enabling rapid translation of discoveries into meaningful, patient‑centered therapies.
Our Mission
Our mission is to advance the understanding, diagnosis, and treatment of rare bronchiectasis diseases by integrating rigorous clinical research with cutting‑edge laboratory science. We are dedicated to characterizing disease trajectories, uncovering the mechanisms that drive airway obstruction and epithelial injury, and validating biomarkers. Through coordinated cores in administration, career development, and pilot project governance, we support collaborative science, train the next generation of rare disease investigators, and ensure that patient and family voices remain central to our work. Together, we strive to accelerate therapeutic discovery and improve the lives of those affected by rare bronchiectasis.